3SBIO: VOLUNTARY ANNOUNCEMENT707 Injection (Anti-VEGF/PD-1 Bispecific Antibody) GrantedBreakthrough Therapy Designation by NMPA
3SBIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
3SBIO: FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2024
3SBIO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
3SBIO: NOTICE OF BOARD MEETING
3SBIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
3SBIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
3SBIO: VOLUNTARY ANNOUNCEMENTCOOPERATION BETWEEN 3SBIO INC. ANDDUALITY BIOLOGICSIN RESPECT OF HER2 ADC DRUG
3SBIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
3SBIO: (1) CANCELLATION OF TREASURY SHARES; AND(2) CHANGE OF ADDRESS OF PRINCIPAL PLACE OFBUSINESS IN HONG KONG
3SBIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
3SBIO: VOLUNTARY ANNOUNCEMENTCOOPERATION BETWEEN SHENYANG SUNSHINEAND SUNSHINE LAKE PHARMA IN RESPECT OFCLIFUTINIB BESYLATE
3SBIO: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY CHIEF FINANCIAL OFFICER
3SBIO: VOLUNTARY ANNOUNCEMENT - MANDI RANKED THE FIRST PLACE ON MULTIPLE PLATFORMS IN "DOUBLE 11" OF 2024
3SBIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
3SBIO: VOLUNTARY ANNOUNCEMENTSHENYANG SUNSHINE HAS ENTERED INTO A COOPERATION AGREEMENTWITH HAIHE BIOPHARMA IN RESPECT OF PACLITAXEL ORAL SOLUTION
3SBIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
3SBIO: 2024 Interim Report
3SBIO: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THECONNECTED TRANSACTION ON GRANT OFSHARE AWARDS TO CONNECTED PERSONS PURSUANTTO THE SHARE AWARD SCHEME
3SBIO: CONNECTED TRANSACTIONGRANT OF SHARE AWARDS TO CONNECTED PERSONSPURSUANT TO THE SHARE AWARD SCHEME